Academic Urology Unit, Royal Marsden NHS Foundation Trust, Sutton, UK.
Curr Opin Urol. 2012 May;22(3):210-5. doi: 10.1097/MOU.0b013e328351dc47.
The long-term safety and effectiveness of active surveillance depends on our ability to select appropriate patients and trigger delayed treatment in those who need it, whereas avoiding intervention in those who do not. In this review, we will consider how recent advances have influenced patient selection for active surveillance and review the range of different intervention triggers that have been proposed.
Several large surveillance cohort studies have been reported recently showing excellent medium-term outcomes in well selected patients, with approximately a third of patients going on to have deferred treatment. Debate continues on the most appropriate eligibility criteria for active surveillance and what triggers for intervention should be used. There is growing interest in the role of transperineal template biopsies and multiparametric MRI, both for patient selection and in identifying triggers for intervention.
Active surveillance is a well tolerated treatment option in well selected groups of patients. There is no 'one size fits all' set of criteria for patient selection or triggers for intervention but decisions can be guided by information from histology, prostate-specific antigen kinetics and imaging.
主动监测的长期安全性和有效性取决于我们选择合适患者的能力,并在需要时触发延迟治疗,同时避免对不需要治疗的患者进行干预。在本次综述中,我们将考虑最近的进展如何影响主动监测的患者选择,并回顾提出的各种不同干预触发因素。
最近报道了几项大型监测队列研究,结果显示在选择良好的患者中具有出色的中期结果,约有三分之一的患者接受了延迟治疗。关于主动监测的最合适入选标准以及应使用何种干预触发因素仍存在争议。人们越来越关注经会阴模板活检和多参数 MRI 在患者选择和确定干预触发因素方面的作用。
在选择良好的患者群体中,主动监测是一种耐受良好的治疗选择。没有适用于所有患者的入选标准或干预触发因素的“一刀切”方案,但可以根据组织学、前列腺特异性抗原动力学和影像学信息来指导决策。